Over 4,000 people enroll in Phase II trial of local COVID-19 vaccine

Over 4,000 people in Taiwan have enrolled in the second-stage clinical trial of a domestic COVID-19 vaccine, of whom around 3,700 have already received an injection, the vaccine's developer, Medigen Vaccine Biologics Corp. (MVC), announced Tuesday.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)